These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36927800)

  • 1. Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients.
    Pogosova-Agadjanyan EL; Hua X; Othus M; Appelbaum FR; Chauncey TR; Erba HP; Fitzgibbon MP; Jenkins IC; Fang M; Lee SC; Moseley A; Naru J; Radich JP; Smith JL; Willborg BE; Willman CL; Wu F; Meshinchi S; Stirewalt DL
    Biomark Res; 2023 Mar; 11(1):31. PubMed ID: 36927800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
    Williams MS; Basma NJ; Amaral FMR; Wiseman DH; Somervaille TCP
    BMC Cancer; 2021 Oct; 21(1):1153. PubMed ID: 34711181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report.
    Pogosova-Agadjanyan EL; Moseley A; Othus M; Appelbaum FR; Chauncey TR; Chen IL; Erba HP; Godwin JE; Fang M; Kopecky KJ; List AF; Pogosov GL; Radich JP; Willman CL; Wood BL; Meshinchi S; Stirewalt DL
    Biopreserv Biobank; 2018 Feb; 16(1):42-52. PubMed ID: 29172682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report.
    Pogosova-Agadjanyan EL; Moseley A; Othus M; Appelbaum FR; Chauncey TR; Chen IL; Erba HP; Godwin JE; Jenkins IC; Fang M; Huynh M; Kopecky KJ; List AF; Naru J; Radich JP; Stevens E; Willborg BE; Willman CL; Wood BL; Zhang Q; Meshinchi S; Stirewalt DL
    Biomark Res; 2020; 8():29. PubMed ID: 32817791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD117/CD34 expression in leukemic blasts.
    Wells SJ; Bray RA; Stempora LL; Farhi DC
    Am J Clin Pathol; 1996 Aug; 106(2):192-5. PubMed ID: 8712172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.
    van Luijn MM; Chamuleau ME; Thompson JA; Ostrand-Rosenberg S; Westers TM; Souwer Y; Ossenkoppele GJ; van Ham SM; van de Loosdrecht AA
    Haematologica; 2010 Mar; 95(3):485-93. PubMed ID: 19903675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AC133 antigen as a prognostic factor in acute leukemia.
    Lee ST; Jang JH; Min YH; Hahn JS; Ko YW
    Leuk Res; 2001 Sep; 25(9):757-67. PubMed ID: 11489469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A higher percentage of leukemic blasts with vacuoles predicts unfavorable outcomes in patients with acute myeloid leukemia.
    Song J; Shang B; Pei Y; Shi M; Niu X; Dou L; Drokow EK; Xu F; Bai Y; Sun K
    Leuk Res; 2021 Oct; 109():106638. PubMed ID: 34116372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TIM-3 Expression Level on AML Blasts Correlates With Presence of Core Binding Factor Translocations Rather Than Clinical Outcomes.
    Hong J; Xia L; Huang Z; Yuan X; Liang X; Dai J; Wu Z; Liang L; Ruan M; Long Z; Cheng X; Chen X; Ni J; Ge J; Li Q; Zeng Q; Xia R; Wang Y; Yang M
    Front Oncol; 2022; 12():879471. PubMed ID: 35494006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dielectrophoretic Microfluidic Chip Enables Single-Cell Measurements for Multidrug Resistance in Heterogeneous Acute Myeloid Leukemia Patient Samples.
    Khamenehfar A; Gandhi MK; Chen Y; Hogge DE; Li PC
    Anal Chem; 2016 Jun; 88(11):5680-8. PubMed ID: 27149245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study.
    Vergez F; Green AS; Tamburini J; Sarry JE; Gaillard B; Cornillet-Lefebvre P; Pannetier M; Neyret A; Chapuis N; Ifrah N; Dreyfus F; Manenti S; Demur C; Delabesse E; Lacombe C; Mayeux P; Bouscary D; Recher C; Bardet V
    Haematologica; 2011 Dec; 96(12):1792-8. PubMed ID: 21933861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High expression of COMMD7 is an adverse prognostic factor in acute myeloid leukemia.
    Li K; Chen L; Zhang H; Wang L; Sha K; Du X; Li D; Zheng Z; Pei R; Lu Y; Tong H
    Aging (Albany NY); 2021 Apr; 13(8):11988-12006. PubMed ID: 33891561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidimensional study of the heterogeneity of leukemia cells in t(8;21) acute myelogenous leukemia identifies the subtype with poor outcome.
    Jiang L; Li XP; Dai YT; Chen B; Weng XQ; Xiong SM; Zhang M; Huang JY; Chen Z; Chen SJ
    Proc Natl Acad Sci U S A; 2020 Aug; 117(33):20117-20126. PubMed ID: 32747558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia.
    Ross JF; Wang H; Behm FG; Mathew P; Wu M; Booth R; Ratnam M
    Cancer; 1999 Jan; 85(2):348-57. PubMed ID: 10023702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a hierarchy in human acute myeloid leukemia progenitor cells.
    Sutherland HJ; Blair A; Zapf RW
    Blood; 1996 Jun; 87(11):4754-61. PubMed ID: 8639846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute mixed lineage leukemia: clinicopathologic correlations and prognostic significance.
    Mirro J; Zipf TF; Pui CH; Kitchingman G; Williams D; Melvin S; Murphy SB; Stass S
    Blood; 1985 Nov; 66(5):1115-23. PubMed ID: 3931724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunosuppressive role of CD11b
    Hyun SY; Na EJ; Jang JE; Chung H; Kim SJ; Kim JS; Kong JH; Shim KY; Lee JI; Min YH; Cheong JW
    Cancer Med; 2020 Oct; 9(19):7007-7017. PubMed ID: 32780544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum-free generation and quantification of functionally active Leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes.
    Kufner S; Fleischer RP; Kroell T; Schmid C; Zitzelsberger H; Salih H; de Valle F; Treder W; Schmetzer HM
    Cancer Immunol Immunother; 2005 Oct; 54(10):953-70. PubMed ID: 15789235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High frequency of CD34+CD38-/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia.
    Plesa A; Dumontet C; Mattei E; Tagoug I; Hayette S; Sujobert P; Tigaud I; Pages MP; Chelghoum Y; Baracco F; Labussierre H; Ducastelle S; Paubelle E; Nicolini FE; Elhamri M; Campos L; Plesa C; Morisset S; Salles G; Bertrand Y; Michallet M; Thomas X
    World J Stem Cells; 2017 Dec; 9(12):227-234. PubMed ID: 29321824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.
    Kern W; Haferlach T; Schoch C; Loffler H; Gassmann W; Heinecke A; Sauerland MC; Berdel W; Buchner T; Hiddemann W
    Blood; 2003 Jan; 101(1):64-70. PubMed ID: 12393605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.